tocilizumab,cevostamab
roche
['mmsm', 'toci', 'cevostamab']
markedly decreased crs in the toci group. gr1/2 in both cohorts. crs onset d1. 36% nontoci group needed toci post; 19% in the toci group needed post #cevostamab toci.
#ash22 #mmsm 
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.